NetScientific PLC - PDS prioritise PDS0101 in high risk HPV to Phase 2
Portfolio Company PDS Biotechnology to prioritise lead immunotherapy treatment in high-risk human papillomavirus (HPV) into Phase 2 studies
"It is great to see the growing momentum at PDS following the positive Phase I data for their lead immunotherapy treatment for high-risk HPV. They are set to advance their combination studies with PDS0101 in various advanced HPV-associated cancers into Phase 2 clinical studies which are partnered with top leaders in the field. As a shareholder in PDS, we continue to provide our support and look forward to hearing updates on the progress of PDS0101 in the future."
# # #
Below is the full announcement made today by PDS Biotechnology:
Data demonstrated regression of lesions in 60% of patients
"Our intent is to continue to advance our previously announced combination studies with PDS0101 in various advanced HPV-associated cancers. These phase 2 clinical studies are partnered with top leaders in the field. We also intend to rapidly progress PDS0102 (targeting prostate and breast cancers), PDS0103 (targeting colon, lung, ovarian cancers) and PDS0104 (targeting melanoma) into human clinical trials in combination with checkpoint inhibitors. This approach has been recently supported by promising Phase 1 clinical outcome data," said Dr.
As a result of the recent data showing strong CD8+ T-cell induction and the subsequent decision to prioritize the platform's application in combination therapies addressing advanced cancer, the Company no longer anticipates starting a Phase 2 study to evaluate PDS0101 monotherapy in CIN2/3 as previously reported.
About the Versamune® Platform Technology Versamune® is a proprietary, synthetic lipid-based T-cell activating platform. PDS Biotechnology's pipeline of Versamune®-based products, which are administered by subcutaneous injection, provides strong activation of type I interferon genes. The Versamune® mechanism of action also involves effective presentation of tumor antigens via the MHC Class I and Class II pathways. These mechanisms together promote strong in-vivo induction of polyfunctional tumor-targeting CD8+ T-cells. Versamune®-based immunotherapies have been demonstrated to alter the tumor micro-environment in preclinical mechanism of action studies, thus further enhancing the ability of Versamune®-induced T-cells to effectively kill tumor cells. Preclinical data demonstrating the novel multi-functional mechanism of action of the Versamune® platform technology and the resulting superior T-cell induction and unique regression of advanced tumors were published in the
About PDS Biotechnology and PDS0101 PDS Biotechnology is a clinical stage immuno-oncology company with a growing pipeline of clinical-stage immunotherapies to treat various HPV-associated cancers, including head and neck cancer, cervical and anal cancers. PDS0101 includes the Versamune® immune-activating platform and a mixture of HPV16 E6 and E7 peptide antigens designed to induce cytolytic T-cell responses against HPV expressed in patients with HPV-associated cancers. Clinical outcome findings from the PDS0101 Phase 1 clinical study demonstrated unique in-vivo systemic induction of high levels of granzyme-b inducing HPV-specific killer T-cells associated with observed clinical responses (regression and elimination of pre-cancerous lesions) in the majority of evaluable patients treated with PDS0101 monotherapy, and a lack of dose limiting toxicities at all tested doses. Versamune® is a registered trademark of PDS Biotechnology Corporation,
For full release and additional information about PDS, please visit www.pdsbiotech.com.
# # #
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.
For more information, please contact:
| || |
Tel: +44 (0)20 3514 1800
WHIreland (NOMAD, Financial Adviser and Broker)
Tel: +44 (0)20 7220 1666
MO PR ADVISORY (Press Contact)
Tel: +44 (0)78 7644 4977
For more information, please visit the website at www.NetScientific.net
This information is provided by RNS, the news service of the
Quick facts: Netscientific PLC
Market Cap: £4.52 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE